HSP90AB1 and plasma cell myeloma: As mentioned above, HDAC6-specific inhibitors are widely used in multiple myeloma, studies have shown that As2O3 plays an anti-multiple myeloma role by inhibiting the activity of HDAC6, promoting the acetylation of α-tubulin, reducing the function of Hsp90, and leading to the inactivation of NF-κB.